# Enzalutamide and Decitabine in Treating Patients With Metastatic Castration Resistant Prostate Cancer

> **NCT03709550** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **Roswell Park Cancer Institute**

## Conditions studied

- Castration Levels of Testosterone
- Castration-Resistant Prostate Carcinoma
- Metastatic Prostate Carcinoma in the Soft Tissue
- Prostate Carcinoma Metastatic in the Bone
- PSA Level Greater Than or Equal to Two
- PSA Progression
- Stage IV Prostate Cancer AJCC v8
- Stage IVA Prostate Cancer AJCC v8
- Stage IVB Prostate Cancer AJCC v8

## Interventions

- **DRUG:** Decitabine
- **DRUG:** Enzalutamide

## Key facts

- **NCT ID:** NCT03709550
- **Lead sponsor:** Roswell Park Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2021-04-15
- **Primary completion:** 2023-04-15
- **Final completion:** 2024-04-15
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** lack of funding
- **Last updated:** 2022-10-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03709550

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03709550, "Enzalutamide and Decitabine in Treating Patients With Metastatic Castration Resistant Prostate Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03709550. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*